Effects of Botulinum Toxin A on Selective Motor Control in Cerebral Palsy: A Simultaneous Assessment of Upper and Lower Extremities
Overview
- Phase
- Phase 4
- Intervention
- Conventional Physical Therapy
- Conditions
- Cerebral Palsy Spastic Diplegia
- Sponsor
- Gaziosmanpasa Research and Education Hospital
- Enrollment
- 40
- Locations
- 1
- Primary Endpoint
- SCALE (Selective Control Assessment of the Lower Extremity)
- Status
- Completed
- Last Updated
- last month
Overview
Brief Summary
The aim of this study is to investigate the effects of Botulinum Neurotoxin-A (BoNT-A) injection applied to spastic muscles on pain sensation and Selective Motor Control (SMC) in cases diagnosed with diplegic spastic Cerebral Palsy.
Detailed Description
Cerebral Palsy (CP) is a non-progressive, permanent neurological disorder that occurs in the fetal or infant brain. CP, defined as a group of non-progressive movement and posture disorders, is the most common cause of neurological disability in children. The primary cause is insufficient oxygen supply to the fetus and brain asphyxia. However, other underlying factors may also be involved. Preterm birth is the most important risk factor that should be considered first. Musculoskeletal problems mainly arise due to positive findings such as spasticity, clonus, hyperreflexia related to Upper Motor Neuron damage, and negative findings such as weakness and reduced Selective Motor Control (SMC). Selective Motor Control (SMC) is the ability to achieve muscle activation in an appropriate pattern, in an isolated manner, to produce a voluntary movement or posture. Studies have shown that the impact of SMC on motor performance is as significant as routinely measured issues such as spasticity and contracture. Pain is a common problem in CP, with more than half of children and adults with CP reporting pain as an issue. Assessing pain in children with CP is particularly challenging, especially in those who cannot express themselves verbally. The most common potential causes of pain include neuromuscular problems such as muscle spasms, musculoskeletal problems like hip dislocation and scoliosis, and gastrointestinal issues such as gastroesophageal reflux and constipation. Botulinum Neurotoxin-A (BoNT-A), when applied intramuscularly, inhibits presynaptic acetylcholine (Ach) release by preventing the fusion of Ach vesicles with the plasma membrane. BoNT-A acts on the motor endplate, providing reversible chemical denervation. It is used for localized spasticity and can be applied to multiple muscles in a single session. It is generally used for spasticity starting from the age of 2. Along with rehabilitation, it aids in motor learning, promotes functional progression, and delays or prevents the development of orthopedic deformities. The aim of our study is to investigate the effects of BoNT-A injections into spastic muscles on pain perception and SMC in patients with diplegic spastic CP.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients diagnosed with Cerebral Palsy
- •Between the ages of 4-12
- •GMFCS (Gross Motor Function Classification System)1-4
- •Patients who have received an appropriate indication for BoNT-A injection from an experienced physiatrist
- •Patients who have not had botulinum toxin administered in the last 6 months
Exclusion Criteria
- •Mental retardation
- •Have an intrathecal baclofen pump for spasticity treatment or history of soft tissue and/or bone surgery
- •Underwent dorsal rhizotomy
- •Have an active infection or a localized skin infection at the injection site
- •Using aminoglycoside antibiotics
- •Contracture
Arms & Interventions
Conventional Physical Therapy Group
Conventional rehabilitation, personalized and administered under the guidance of a physiotherapist
Intervention: Conventional Physical Therapy
Botulinum toxin injection group
Administration of botulinum toxin injection prior to the conventional rehabilitation program
Intervention: OnabotulinumtoxinA
Botulinum toxin injection group
Administration of botulinum toxin injection prior to the conventional rehabilitation program
Intervention: Conventional Physical Therapy
Outcomes
Primary Outcomes
SCALE (Selective Control Assessment of the Lower Extremity)
Time Frame: six weeks
SCALE; it is a scale that can be easily applied in outpatient clinic conditions, does not require any equipment. A total of 5 regions are assessed: the hip, knee, ankle, subtalar joint, and toes. Scoring is as follows: 0 (cannot be performed), 1 (impaired SMC), and 2 (normal). If the patient performs the movement correctly within 3 seconds, without moving any other joint besides the one being evaluated and without any mirror movement, it is considered normal SMC (2 points). If there is movement in another joint, mirror movement occurs, the range of motion is less than 50% of the passive ROM (Range Of Motion), or the movement takes longer than 3 seconds, it is considered impaired SMC (1 point). If the patient cannot initiate the movement or develops flexor/extensor synergy, it is scored as unachievable (0 points).
Boyd and Graham SMC Test
Time Frame: six weeks
This test, developed by Boyd and Graham, aims to evaluate the Selective Motor Control (SMC) of ankle dorsiflexion. The test assesses the patient's ability to activate the muscles responsible for ankle dorsiflexion (DF). It consists of 5 items and is scored on a scale from 0 to 4. 0: No movement at all when asked to dorsiflexion the foot. 1. Limited dorsiflexion achieved primarily through the use of extensor hallucis longus (EHL) and/or extensor digitorum brevis (EDB). 2. Limited dorsiflexion achieved using EHL, EDB, and some tibialis anterior (TA) muscle. 3. Dorsiflexion primarily using TA, but with accompanying hip and knee flexion. 4. Isolated selective ankle dorsiflexion (DF) achieved through isolated TA muscle activity without hip or knee flexion.
Visual Analog Scale (VAS)
Time Frame: six weeks
The Visual Analog Scale (VAS) is a very simple and easy-to-use pain scale where patients assess the intensity of their pain between "no pain" (0 points) and "unbearable pain" (10 points). The patient rates their pain on a scale from 0 to 10: 0: No pain 1-3: Mild pain 4-6: Moderate pain 7-10: Severe pain
Secondary Outcomes
- SCUES (Selective Control of the Upper Extremity Scale)(six weeks)
- Functional Independence Measure for Children (WeeFIM)(six weeks)
- Pediatric Quality of Life Inventory (PedsQL)(six weeks)
- Child and Adolescent Participation Questionnaire (CASP)(six weeks)